. The RNA expression profile of selected genes was validated using quantitative RT PCR. Protein expression was analyzed by immunohistochemistry (IHC). Explants of newly GB were treated with temozolomide, radiotherapy and anti-CXCR4 (AMD3100). RESULTS: Twenty nine patients were included with median age of 57.1 years (37.2-74.1). The RT2Profiler PCR arrays results allowed a selection of seven genes: VEGFA, VEGFR2, VEGFR1, Adrenomedullin, SDF1, CXCR4, and HIF1a. The steady state levels of CXCR4 RNA at recurrence was significantly increased (p ¼ 0.029) while HIF1a RNA was significantly decreased (p ¼ 0.009). A trend for a decrease of VEGFR2 RNA (p ¼ 0.081) and an increase of SDF1 RNA (p ¼ 0.107) was observed. Changes of SDF1 RNA tended to be correlated to changes of CXCR4 RNA (p ¼ 0.077) and inversely correlated to changes of HIF1 a RNA (p ¼ 0.064). By IHC, VEGFR2 staining was significantly decreased at recurrence (p ¼ 0.004) while SDF1 expression tended to increased (p ¼ .096). Medians initial and at recurrence overall survival (OSI and OSR) of this selected population were 25.5 (95% confidence interval (CI) 17-34) and 11.4 (95%CI 9-13.9) months respectively. By multivariate analysis, VEGFR2 RNA initial and at recurrence levels were significantly correlated to OSI (p ¼ 0.019, Hazard ratio (HR) ¼3.650) and OSR (p ¼ 0.024, HR ¼ 2.536) while HIF1 a RNA level at baseline was correlated to OSI (p ¼ 0.012, HR ¼ 0.300). In newly GB explants, a higher anti-tumoral effect was observed with the combination of AMD3100 and CTRT versus CTRT alone. CONCLUSION: Acquired resistance of GB to chemo-radiation could be associated with a switch of angiogenic pattern from VEGFR2-HIF1a to SDF1-CXCR4 pathway, leading to new perspectives in angiogenic modulation and GB treatment.
